Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 27, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma to Present at Jefferies 2015 Healthcare Conference on June 4th

TEL AVIV, Israel, May 27, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that Colin Foster, President and...
May 19, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma Reports First Quarter Financial Results

TEL AVIV, Israel, May 19, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the first...
April 09, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma Announces Granting of Fast Track Designation by the FDA for Cabaletta in Oculopharyngeal Muscular Dystrophy (OPMD)

TEL AVIV, Israel, April 9, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company announced today that the United States Food and...
March 30, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma Announces Positive in vivo Preclinical Proof-of-Concept Results of Its Cabaletta Platform in Spinocerebellar Ataxia Type 3 (SCA3)

TEL AVIV, Israel, March 30, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company announced today positive in vivo...
March 26, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma Announces Positive Preclinical Proof-of-Concept Results of Its Novel Mitochondrial Protein Replacement Platform in Friedreich's Ataxia

TEL AVIV, Israel, March 26, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company announced today positive preclinical in vitro...
March 12, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Receives IND Clearance to Commence Clinical Trial for Cabaletta for the Treatment of OPMD

TEL AVIV, Israel, March 12, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that the U.S. Food and Drug...
March 05, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma to Present at the 27th Annual ROTH Investor Conference

TEL AVIV, Israel, March 5, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that Colin Foster, President and...
February 24, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Receives Notice of Allowance From USPTO Covering Cabaletta for the Treatment of OPMD

TEL AVIV, Israel, Feb. 24, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today it has received a notice of...
February 17, 2015 08:00 ET | Source: Bioblast Pharma Ltd.

BioBlast Pharma Reports Fourth Quarter Financial Results

TEL AVIV, Israel, Feb. 17, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with...
February 10, 2015 09:22 ET | Source: Bioblast Pharma Ltd.

Bio Blast Pharma to Release Fourth Quarter and Fiscal Year 2014 Results on Tuesday, February 17

TEL AVIV, Israel, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Bio Blast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients...